Low-Dose Nivolumab with or without Ipilimumab as Adjuvant Therapy Following the Resection of Melanoma Metastases: A Sequential Dual Cohort Phase II Clinical Trial

SIMPLE SUMMARY: Optimal dosing and duration of adjuvant treatment with PD-1 immune checkpoint inhibitors in melanoma patients have not been established. The investigated low-dose regimen of nivolumab with or without ipilimumab (in a sequential dual-cohort phase II trial), resulted in a 12-months rel...

Descripción completa

Detalles Bibliográficos
Autores principales: Schwarze, Julia Katharina, Garaud, Soizic, Jansen, Yanina J. L., Awada, Gil, Vandersleyen, Valérie, Tijtgat, Jens, de Wind, Alexandre, Kristanto, Paulus, Seremet, Teofila, Willard-Gallo, Karen, Neyns, Bart
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8833641/
https://www.ncbi.nlm.nih.gov/pubmed/35158952
http://dx.doi.org/10.3390/cancers14030682

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8833641/
https://www.ncbi.nlm.nih.gov/pubmed/35158952
http://dx.doi.org/10.3390/cancers14030682

Ejemplares similares